Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.64 |
| ▸ | AKT1 | P31749 | 1/20 | 0.62 |
| ▸ | AKT2 | P31751 | 1/20 | 0.62 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27384150 | 0.91 | PIK3CA (0.64) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25453104 | 0.90 | PIK3CA (0.65) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25178378 | 0.90 | PIK3CA (0.65) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL31516556 | 0.89 | PIK3CA (0.53) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25679238 | 0.89 | PIK3CA (0.50) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25451593 | 0.89 | PIK3CA (0.70) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25177492 | 0.89 | PIK3CA (0.70) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25451559 | 0.88 | AKT1 (0.65) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL25451278 | 0.88 | AKT1 (0.65) | PIK3CAAKT1AKT2AKT3 | |
| SCHEMBL27384206 | 0.88 | PIK3CA (0.64) | PIK3CAAKT1AKT2AKT3PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| EP-4444714-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118742545-A | Fused heterocyclic compounds as PI3K alpha inhibitors | 南京征祥医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 16/4885AKT2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.